<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1154</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2019-18-2-32-39</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">N-glycosidesindolo[2,3,-a]pyrrolo[3,4,-c]carbazole derivatives chemical structure influence on antitumor activity</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние химической структуры производных N-гликозидов индоло[2,3-а]пирроло[3,4-c]карбазолов на противоопухолевую активность</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kiseleva</surname><given-names>M. P.</given-names></name><name xml:lang="ru"><surname>Киселева</surname><given-names>М. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Sh., Moscow 115478.</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское ш., 24.</p></bio><email>marina-kiselyova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4006-9320</contrib-id><name-alternatives><name xml:lang="en"><surname>Pokrovsky</surname><given-names>V. S.</given-names></name><name xml:lang="ru"><surname>Покровский</surname><given-names>В. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Sh., Moscow 115478; 6 Miklukho-Maklaya St., Moscow 117198.</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское ш., 24; 117198 Москва, ул. Миклухо-Маклая, 6.</p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Borisova</surname><given-names>L. M.</given-names></name><name xml:lang="ru"><surname>Борисова</surname><given-names>Л. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Sh., Moscow 115478.</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское ш., 24.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Golubeva</surname><given-names>I. S.</given-names></name><name xml:lang="ru"><surname>Голубева</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Sh., Moscow 115478.</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское ш., 24.</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ektova</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Эктова</surname><given-names>Л. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Sh., Moscow 115478.</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское ш., 24.</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N. N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of Russia.</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России.</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N. N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Peoples’ Friendship University of Russia.</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский университет дружбы народов».</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2019</year></pub-date><volume>18</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>32</fpage><lpage>39</lpage><history><date date-type="received" iso-8601-date="2019-06-15"><day>15</day><month>06</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-06-15"><day>15</day><month>06</month><year>2019</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1154">https://bioterapevt.abvpress.ru/jour/article/view/1154</self-uri><abstract xml:lang="en"><p><bold>Introduction</bold> . The report considers the prospect of rational approach to the new anticancer agents creation based on indolocarbazole derivatives.</p><p><bold>Objective</bold> . To conduct a comparative study of 12 domestic N-glycosides, indolo[2,3-a]pirrolo[2,3-a]carbazole derivatives in the course of “structure – activity” bond analysis.</p><p><bold>Materials and methods .</bold> The investigation of influence of 12 carbohydrate – containing indolocarbazoles, synthesized in N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of Russia, performed on models of solid transplantable mouse tumors: lung Lewis epidermoid carcinoma and B16 melanoma. The antitumor effect was assessed by Lewis epidermoid carcinoma and B16 melanoma tumor growth inhibition (TGI %) criterion.</p><p><bold>Results</bold> . A variety of indolocarbazoles modifications allowed revealing the dependence of their antitumor properties on the structure of both, the aglycone and the glycoside residue. Imino-nitrogen interchange of atoms in upper heterocycle influences on indocarbazole derivatives antitumor activity change. During a comparative study of 12 N-glycosides indolocarbazole derivatives on lung Lewis epidermoid carcinoma and B16 melanoma models, 8 derivatives showed antitumor activity.</p><p><bold>Conclusion</bold> . The formulated concepts on the modification features in indolocarbazole derivatives structure can be used for more active compounds creation with greater action selectivity. </p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение</bold> . В работе рассматривается перспектива рационального подхода к созданию новых противоопухолевых агентов на основе производных индолокарбазолов.</p><p><bold>Цель исследования</bold> – в ходе анализа связи «структура – активность» провести сравнительное изучение 12 отечественных производных N-гликозидов индоло[2,3-a]пирроло[3,4-с]карбазолов.</p><p><bold>Материалы и методы</bold> . Исследование влияния структуры на противоопухолевую активность 12 углеводосодержащих индолокарбазолов, синтезированных в Национальном медицинском исследовательском центре онкологии им. Н. Н. Блохина, выполняли на солидных моделях перевиваемых опухолей мышей: эпидермоидной карциноме легкого Lewis и меланоме В16. Противоопухолевый эффект оценивали по критерию торможения роста карциномы легкого Lewis и меланомы В16.</p><p><bold>Результаты</bold> . Разнообразие модификаций индолокарбазолов позволило выявить зависимость их противоопухолевых свойств как от структуры агликона, так и от гликозидного остатка. Замена атомов в верхнем гетероцикле по имидному азоту влияет на изменение противоопухолевой активности производных индолокарбазолов с различными и одинаковыми углеводными остатками. При сравнительном изучении 12 производных N-гликозидов индолокарбазолов на моделях карциномы легкого Lewis и меланомы В16 противоопухолевую активность проявили 8 производных.</p><p><bold> Заключение</bold> . Сформулированные положения о модификационных особенностях в структуре производных индолокарбазолов могут быть использованы для создания более активных соединений с высокой избирательностью действия. </p></trans-abstract><kwd-group xml:lang="en"><kwd>indolocarbazole derivatives</kwd><kwd>chemical structure</kwd><kwd>antitumor activity</kwd><kwd>transplantable mouse tumors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>производные индолокарбазолов</kwd><kwd>химическая структура</kwd><kwd>противоопухолевая активность</kwd><kwd>перевиваемые опухоли мышей</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Онкология: справочник практического врача. Под ред. И.В. Поддубной. М.: МЕДпресс-информ., 2009. 768 с. [Oncology: Referencepractitioner. Edn. I.V. Poddubnaya. M.: MEDpressinform., 2009. 768 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Онкология: справочник практического врача. Под ред. И.В. Поддубной. М.: МЕДпресс-информ., 2009. 768 с. [Oncology: Referencepractitioner. Edn. I.V. Poddubnaya. M.: MEDpressinform., 2009. 768 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Семенов А.А. Природные противоопухолевые соединения (структура и механизм действия). Новосибирск: Наука, 1979. 222 с. [Natural antitumor compounds (structure and mechanism of action). Novosibirsk: Nauka, 1979. 222 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Семенов А.А. Природные противоопухолевые соединения (структура и механизм действия). Новосибирск: Наука, 1979. 222 с. [Natural antitumor compounds (structure and mechanism of action). Novosibirsk: Nauka, 1979. 222 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7(1):39–58.</mixed-citation><mixed-citation xml:lang="ru">Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7(1):39–58.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Pereira E.R., Belin L., Sancelme M. et al. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J Med Chem 1996;39(22):4471–7.</mixed-citation><mixed-citation xml:lang="ru">Pereira E.R., Belin L., Sancelme M. et al. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J Med Chem 1996;39(22):4471–7.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Pindur U., Kim Y.S., Mehrabani F. Advances in indolo[2,3-a]carbazole chemistry: design synthesis of protein kinase C and topoisomerase I inhibitors. Curr Med Chem 1999;6(1):29–69.</mixed-citation><mixed-citation xml:lang="ru">Pindur U., Kim Y.S., Mehrabani F. Advances in indolo[2,3-a]carbazole chemistry: design synthesis of protein kinase C and topoisomerase I inhibitors. Curr Med Chem 1999;6(1):29–69.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Deslandes S., Chassaing S., Delfourne E. Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition. Mar Drugs 2009;7(4):754–86. DOI: 10.3390/md7040754.</mixed-citation><mixed-citation xml:lang="ru">Deslandes S., Chassaing S., Delfourne E. Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition. Mar Drugs 2009;7(4):754–86. DOI: 10.3390/md7040754.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Omura S., Ywai Y., Hirano A. et al. A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J Antibiot 1977;30(4):275–82.</mixed-citation><mixed-citation xml:lang="ru">Omura S., Ywai Y., Hirano A. et al. A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J Antibiot 1977;30(4):275–82.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Nettleton D.E., Doyle T.W., Krishnan B. et al. Isolation and structure of rebeccamycin – a new antitumor antibiotic from nocardia aerocoligenes. Tetrahedron Lett 1985;26:4011–4. DOI.org/10.1016/ S0040-4039(00)89280-1.</mixed-citation><mixed-citation xml:lang="ru">Nettleton D.E., Doyle T.W., Krishnan B. et al. Isolation and structure of rebeccamycin – a new antitumor antibiotic from nocardia aerocoligenes. Tetrahedron Lett 1985;26:4011–4. DOI.org/10.1016/ S0040-4039(00)89280-1.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Wada Y., Nagasaki H., Tokuda M. et al. Synthesis of N-protected staurosporinones. J Org Chem 2007;72(6): 2008–14. DOI: 10.1021/jo062184r.</mixed-citation><mixed-citation xml:lang="ru">Wada Y., Nagasaki H., Tokuda M. et al. Synthesis of N-protected staurosporinones. J Org Chem 2007;72(6): 2008–14. DOI: 10.1021/jo062184r.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Prudhomme M. Biological Targets of antitumor indolocarbazoles bearing a sugar moiety. Curr Med Chem AntiCancer Agents 2004;4(6):509–21.</mixed-citation><mixed-citation xml:lang="ru">Prudhomme M. Biological Targets of antitumor indolocarbazoles bearing a sugar moiety. Curr Med Chem AntiCancer Agents 2004;4(6):509–21.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Gescher A. Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol 1998;31:721–8.</mixed-citation><mixed-citation xml:lang="ru">Gescher A. Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol 1998;31:721–8.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Zembower D.E., Zhang H., Lines wala J.P. et al. Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110. Bioorg Med Chem 1999;9:145–50.</mixed-citation><mixed-citation xml:lang="ru">Zembower D.E., Zhang H., Lines wala J.P. et al. Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110. Bioorg Med Chem 1999;9:145–50.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Urasaki Y., Laco G., Takebayashi Y. et al. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506 and its topoisomerase I binding site. Cancer Res 2001;61(2):504–8.</mixed-citation><mixed-citation xml:lang="ru">Urasaki Y., Laco G., Takebayashi Y. et al. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506 and its topoisomerase I binding site. Cancer Res 2001;61(2):504–8.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Ohkubo M., Kojiri K., Kondo H. et al. Synthesis and biological activities of topoisomerase i inhibitors, 6-N-amino analogues of NB-506. Bioorg Med Chem Lett 1999;9(9):1219–24.</mixed-citation><mixed-citation xml:lang="ru">Ohkubo M., Kojiri K., Kondo H. et al. Synthesis and biological activities of topoisomerase i inhibitors, 6-N-amino analogues of NB-506. Bioorg Med Chem Lett 1999;9(9):1219–24.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Preobrazhenskaya M.N., Korbukh I.A. The synthesis and reactions of pyrrole, pyrazole, triazole, indole, indazole and benzotriazole nucleosides and nucleotides. In: Chemistry of Nucleosides and Nu cleo tides. Сh. 3. Ed. L.B. Townsend. New York, London: Plenum Press, 1993. Pp. 1–105.</mixed-citation><mixed-citation xml:lang="ru">Preobrazhenskaya M.N., Korbukh I.A. The synthesis and reactions of pyrrole, pyrazole, triazole, indole, indazole and benzotriazole nucleosides and nucleotides. In: Chemistry of Nucleosides and Nu cleo tides. Сh. 3. Ed. L.B. Townsend. New York, London: Plenum Press, 1993. Pp. 1–105.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Мельник С.Я. Синтез и изучение гликозидов, производных бисиндола и родственных индоло[2,3-а]карбазолов. Под ред. М.И Давыдова, А.Ю. Барышникова Экспериментальная онкология на рубеже веков. М., 2003. С. 281–93. [Melnik S.Ya. Synthesis and study of glycosides, bisindole derivatives and related indolo[2,3-a]carbazoles. Ed. Davydov M.I., Baryshnikov A.Yu. Experimental oncology at the turn of the century. Moscow, 2003. P. 281–93 (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Мельник С.Я. Синтез и изучение гликозидов, производных бисиндола и родственных индоло[2,3-а]карбазолов. Под ред. М.И Давыдова, А.Ю. Барышникова Экспериментальная онкология на рубеже веков. М., 2003. С. 281–93. [Melnik S.Ya. Synthesis and study of glycosides, bisindole derivatives and related indolo[2,3-a]carbazoles. Ed. Davydov M.I., Baryshnikov A.Yu. Experimental oncology at the turn of the century. Moscow, 2003. P. 281–93 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Экспериментальная оценка противоопухолевых препаратов в СССР и США. Под ред. З.П. Софьиной, А.Б. Сыркина (СССР), А. Голдина, А. Кляйна (США). М.: Медицина, 1980. 295 с. [Experimental evaluation ofantitumor drugsin the USSR and the USA. Ed. Z.P. Sofina, A.B. Syrkin (USSR), A. Goldin, A. Klein (USA), M.: Medicine, 1980:296 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Экспериментальная оценка противоопухолевых препаратов в СССР и США. Под ред. З.П. Софьиной, А.Б. Сыркина (СССР), А. Голдина, А. Кляйна (США). М.: Медицина, 1980. 295 с. [Experimental evaluation ofantitumor drugsin the USSR and the USA. Ed. Z.P. Sofina, A.B. Syrkin (USSR), A. Goldin, A. Klein (USA), M.: Medicine, 1980:296 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Трещалина Е.М., Жукова О.С., Герасимова Г.К. и др. Методические рекомендации по доклиническому изучению противоопухолевой активности лекарственных средств. В кн.: Руководство по проведению доклинических исследований лекарственных средств. Ч. 1. Под ред. А.Н. Миронова, Н.Д. Бунятян, А.Н. Васильева и др. М.: Гриф и К, 2012;39:642–57. [Treshchalina Н.M., Zhukova O.S., Gerasimova G.K. et al. Guidelines for preclinical study of the antitumor activity of drugs. In the book: Guidelines for conducting preclinical studies of drugs. Part 1. Ed. A.N. Mironov, N.D. Bunyatyan, A.N. Vasil’yev et al. M.: Grief and K, 2012;39:642–57 (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Трещалина Е.М., Жукова О.С., Герасимова Г.К. и др. Методические рекомендации по доклиническому изучению противоопухолевой активности лекарственных средств. В кн.: Руководство по проведению доклинических исследований лекарственных средств. Ч. 1. Под ред. А.Н. Миронова, Н.Д. Бунятян, А.Н. Васильева и др. М.: Гриф и К, 2012;39:642–57. [Treshchalina Н.M., Zhukova O.S., Gerasimova G.K. et al. Guidelines for preclinical study of the antitumor activity of drugs. In the book: Guidelines for conducting preclinical studies of drugs. Part 1. Ed. A.N. Mironov, N.D. Bunyatyan, A.N. Vasil’yev et al. M.: Grief and K, 2012;39:642–57 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Голубева И.С., Яворская Н.П., Эктова Л.В. и др. Сравнение противоопухолевой активности производных индолокарбазола с углеводными остатками галактозой, арабинозой и заместителями по имидному атому азота. Российский биотерапевтический журнал 2017;16(s1):23. [Golubeva I.S., Yavorskaya N.P., Ektova L.V. et al. Comparison of the antitumor activity of indolocarbazole derivatives with carbohydrate residues galactose, arabinose and substituents on the imide nitrogen atom. Rossiysky bioterapevtichesky zhurnal = Russian Biotherapeutic Journal 2017;16(S):23 (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Голубева И.С., Яворская Н.П., Эктова Л.В. и др. Сравнение противоопухолевой активности производных индолокарбазола с углеводными остатками галактозой, арабинозой и заместителями по имидному атому азота. Российский биотерапевтический журнал 2017;16(s1):23. [Golubeva I.S., Yavorskaya N.P., Ektova L.V. et al. Comparison of the antitumor activity of indolocarbazole derivatives with carbohydrate residues galactose, arabinose and substituents on the imide nitrogen atom. Rossiysky bioterapevtichesky zhurnal = Russian Biotherapeutic Journal 2017;16(S):23 (In Russ.)].</mixed-citation></citation-alternatives></ref></ref-list></back></article>
